Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The disclosure relates to compounds of formula I: Formula I which inhibit ?V-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.

Abstract: A pixel circuit and a display device. The pixel circuit includes a charging unit, a light-emitting unit and an error compensation unit; a voltage storage terminal of the charging unit is connected to a voltage input terminal of the light-emitting unit; one end of the error compensation unit is connected to the voltage storage terminal of the charging unit, a voltage at the voltage storage terminal of the charging unit is used to determine a magnitude of a current flowing through the light-emitting unit; a control terminal of the error compensation unit is configured to receive a light-emitting control signal which is used to control the light-emitting unit to emit light or stop emitting light, the error compensation unit is configured to lower the voltage at the voltage storage terminal of the charging unit when the light-emitting control signal controls the light-emitting unit to emit light.

Abstract: The present application provides a display device, a display panel and a capacitance compensation method thereof. A standard for performing a capacitance compensation on row scan lines in a first display region having fewer pixel units is that total load capacitance of a row scan line of a row adjacent to a second display region is equal to self-load capacitance of a row scan line of any row in the second display region, and that total load capacitance of each of the row scan lines decreases smoothly from the row adjacent to the second display region to a row away from the second display region.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Abstract: The disclosure relates to compounds of formula I: Formula I which inhibit ?V-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Abstract: The present application provides a scan driver, a driving method thereof and an organic light emitting display. The scan driver includes a first driving area and a second driving area. The first driving area includes a number of first driving units, and the number of the first driving units sequentially sends a first driving signal and a third driving signal to a scan line. The second driving area includes a number of second driving units, and the number of the second driving units sequentially sends a second driving signal to the scan line.

Abstract: A pixel circuit and a display device. The pixel circuit includes a charging unit, a light-emitting unit and an error compensation unit; a voltage storage terminal of the charging unit is connected to a voltage input terminal of the light-emitting unit; one end of the error compensation unit is connected to the voltage storage terminal of the charging unit, a voltage at the voltage storage terminal of the charging unit is used to determine a magnitude of a current flowing through the light-emitting unit; a control terminal of the error compensation unit is configured to receive a light-emitting control signal which is used to control the light-emitting unit to emit light or stop emitting light, the error compensation unit is configured to lower the voltage at the voltage storage terminal of the charging unit when the light-emitting control signal controls the light-emitting unit to emit light.

Abstract: The present application provides a display device, a display panel and a capacitance compensation method thereof. A standard for performing a capacitance compensation on row scan lines in a first display region having fewer pixel units is that total load capacitance of a row scan line of a row adjacent to a second display region is equal to self-load capacitance of a row scan line of any row in the second display region, and that total load capacitance of each of the row scan lines decreases smoothly from the row adjacent to the second display region to a row away from the second display region.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: A pixel circuit includes: nine transistors named after the first through the ninth, a capacitor, and a light emitting diode. A first electrode of the fourth transistor is connected to second electrode of third transistor, control end of first transistor and first polar plate of capacitor. A second electrode of fourth transistor is connected to second electrode of seventh transistor. A first electrode of seventh transistor is connected to anode of the light emitting diode and second electrode of the sixth transistor. A first electrode of the sixth transistor is connected to second electrode of the first transistor and first electrode of the third transistor. A second electrode is connected to first electrode of the first transistor, first electrode of the ninth transistor, and second electrode of the fifth transistor. A second electrode is connected to second polar plate of the capacitor and second electrode of the ninth transistor.

Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.